A
5.26
-0.05 (-0.94%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Alector, Inc. | Bearish | Bullish |
Stockmoo Score
0.2
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Euclidean Capital Llc | 30 Jun 2024 | 1,307,858 |
| 52 Weeks Range | ||
| Median | 35.00 (565.40%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Jun 2024 | 35.00 (565.40%) | Buy | 4.19 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GRASSO MARC | - | 4.72 | -7,297 | -34,442 |
| KENKARE-MITRA SARA | - | 4.72 | -13,926 | -65,731 |
| ROMANO GARY | - | 4.72 | -8,478 | -40,016 |
| ROSENTHAL ARNON | - | 4.72 | -26,499 | -125,075 |
| Aggregate Net Quantity | -56,200 | |||
| Aggregate Net Value ($) | -265,264 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.72 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROMANO GARY | Officer | 03 Sep 2024 | Sell (-) | 8,478 | 4.72 | 40,016 |
| ROSENTHAL ARNON | Officer | 03 Sep 2024 | Sell (-) | 26,499 | 4.72 | 125,075 |
| GRASSO MARC | Officer | 03 Sep 2024 | Sell (-) | 7,297 | 4.72 | 34,442 |
| KENKARE-MITRA SARA | Officer | 03 Sep 2024 | Sell (-) | 13,926 | 4.72 | 65,731 |
| Date | Type | Details |
|---|---|---|
| 29 Aug 2024 | Announcement | Alector to Participate in Upcoming Healthcare Conferences |
| 07 Aug 2024 | Announcement | Alector Reports Second Quarter 2024 Financial Results and Provides Business Update |
| 31 Jul 2024 | Announcement | Alector to Host Mid-Year Earnings Conference Call |
| 28 Jul 2024 | Announcement | Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®) |
| 23 Jul 2024 | Announcement | Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024 |
| 20 Jun 2024 | Announcement | Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |